Zepbound Injection Sites: Where to Inject and How to Rotate

Zepbound goes under the skin of your stomach, your thigh or the back of your upper arm, and the upper arm is a spot someone else should inject for you. Change the exact spot every week. The FDA label says the drug reaches similar levels in the blood from all three areas, so no site is the "best" one for weight loss. Pick the one you can reach comfortably and keep rotating.

Mounjaro is the same medicine, tirzepatide, and its injection sites are identical. Zepbound and Mounjaro are the two FDA-approved tirzepatide products, both made by Eli Lilly. Zepbound is approved for weight reduction and for obstructive sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes. Everything below comes from the prescribing information and the patient Instructions for Use for each one, the paperwork that comes in the box. It's general information and isn't a substitute for the injection training your own provider gives you.

Where to Inject Zepbound and Mounjaro

The prescribing information puts it in one line: inject "subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm." Subcutaneous means into the fatty layer just under the skin. Not the muscle. Not a vein. The patient Medication Guide says it directly: "Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously)."

The three sites side by side:

Site	Where exactly	Who can inject	Notes from the label
Stomach (abdomen)	Under the skin of the belly, at least 2 inches from the belly button	You or another person	The 2-inch rule is spelled out in the KwikPen instructions
Thigh	Under the skin of the thigh	You or another person	Similar drug exposure to the other two sites
Back of the upper arm	Under the skin on the back of the arm	Another person	The label says someone else should give this one
Every site	A new spot each week, even inside the same area	Anyone	Skip skin that is tender, bruised, scaly, hard, scarred or damaged

That's the whole list. No hip, no buttock, no shoulder muscle. If you've seen a video showing a fourth site, it isn't on the label.

The stomach

Most people start here because it's easy to see and easy to reach while seated. The Instructions for Use for the KwikPen tell you to stay "at least 2 inches from the belly button." If it helps, measure it once with a ruler so you know what 2 inches looks like on you. Outside that circle, the belly gives you a wide area to move around in from week to week.

The thigh

The label names the thigh and doesn't narrow it further in the text. It's a good second option, and a useful one if your belly is tender, bruised or simply needs a break. You can inject it yourself while sitting down.

The back of the upper arm

This is the one site the instructions reserve for another person: "Another person should give you the injection in the back of your upper arm." They don't explain why, but try it and the reason is obvious. You can't see the spot, and you can't hold a pen flat and steady against the back of your own arm with your other hand. If a partner or family member has learned the technique, the arm adds a third area to your rotation.

Does the Injection Site Change How Well Tirzepatide Works?

No. This is the question behind a lot of "best spot for weight loss" videos, and the label answers it plainly. Under absorption, the Zepbound prescribing information states: "Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm." The Mounjaro label carries the same sentence.

"Exposure" is how much of the drug reaches your bloodstream over time. Similar exposure from all three sites means the stomach doesn't burn more belly fat and the thigh doesn't slim your legs. Tirzepatide works through the whole body once it's absorbed, wherever the needle went in.

So choose your site on comfort and convenience. Where do you bruise less? Which spot can you reach without twisting? That's your answer, and it's allowed to change.

How to Rotate Your Injection Sites

Rotating is in the label for a reason. The Instructions for Use tell you to "change (rotate) your injection site each week," and they add a detail people often miss: "You may use the same area of your body but be sure to choose a different injection site in that area."

In other words, you can inject your stomach every week for months, as long as it isn't the same spot. Rotation is about the exact spot, not the body area.

The vial instructions explain what rotation prevents. Injecting the same spot over and over raises your risk of lipodystrophy (pits in the skin, or thickened skin) and localized cutaneous amyloidosis (lumps under the skin). Both make the skin a worse place to inject, and the instructions say not to inject where skin has pits, is thickened or has lumps.

A simple way to rotate, if you like a system:

• Picture your belly as four squares around the belly button, outside the 2-inch circle, and move clockwise one square each week
• Alternate left and right thigh
• Write the spot down with the date, in a notes app or on the calendar where you track injection day
• Use a fresh spot an inch or so away from last week's if you stay in the same square

None of that is in the label. It's a habit that makes "a different site in that area" easy to keep without thinking about it.

Where Not to Inject

The Instructions for Use list the skin to skip. Don't inject where the skin is:

• Tender, bruised, scaly or hard
• Scarred or damaged
• Pitted, thickened or lumpy
• Already being used for another medicine

That last one matters if you take other injectables. The Zepbound vial instructions say: "Do not mix ZEPBOUND with any other medicine. Do not inject ZEPBOUND in the same injection site used for other medicines."

For people with diabetes who also use insulin, the Mounjaro prescribing information is specific. The two go in as separate injections and are never mixed. "It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other."

How to Give the Injection

Lilly sells tirzepatide in several forms: a single-dose pen, a single-dose vial, a multi-dose vial and a KwikPen that holds four doses. The injection sites are the same for all of them. The steps differ, which is why the label asks providers to train patients on their exact device and to retrain them if the device changes. Your own Instructions for Use always win over any summary, this one included.

A few points from the instructions that apply across the board:

• Wash your hands first. Every version of the instructions starts there.
• Look at the medicine before you inject. It should be clear and colorless to slightly yellow. Don't use it if it's cloudy, frozen, discolored or has particles in it.
• No need to warm it up: "It is not necessary to warm the pen to room temperature," per the single-dose pen instructions.
• Pinch or not? With a vial and syringe, the instructions say your provider should tell you whether to pinch the skin first.
• Hold still. On the single-dose pen, press and hold the button for up to 10 seconds and listen for two clicks. With a vial and syringe, the needle stays in your skin for at least 5 seconds after you push the plunger.
• Don't rub afterward. A drop of liquid or blood on the skin is normal; press a cotton ball or gauze on it.

Used pens and needles go in an FDA-cleared sharps container, not the household trash. Needles and syringes are never reused or shared. The label goes further for the KwikPen: never share one between people, "even if the pen needle is changed."

How much you inject, and how that changes over time, is a separate topic. Our tirzepatide dosage chart covers it. This post stays on where and how the needle goes in.

Injection Site Reactions: What's Normal

Some redness or tenderness at the spot is common with any weekly injection, and the label tracks it. In the two main Zepbound weight trials, injection site reactions showed up in 6 to 8 percent of people taking Zepbound, against 2 percent on placebo. That category covered bruising, redness, itching, pain and rash at the site.

One finding in the label is worth knowing. Some people develop antibodies to tirzepatide during treatment. In those trials, site reactions were more frequent in people who developed antibodies (11.3 percent) than in people who didn't (1 percent). The label reports this as a pattern in the trials. It doesn't say antibodies cause the reactions, and it isn't something you can check at home.

A mild reaction that fades is something to mention at your next visit. A few things are different and call for your provider sooner:

• A reaction that keeps getting worse, or spreads well past the injection spot
• Skin that stays lumpy, pitted or thickened, which is the rotation problem described above
• A reaction that doesn't go away

And one is an emergency. The Medication Guide says to stop using the medicine and get medical help right away for signs of a serious allergic reaction: swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or a very rapid heartbeat.

Where the Injection Fits in the Bigger Plan

Getting the needle in the right place is the easy part. The harder part is everything around the medicine: eating enough protein while your appetite is low, keeping muscle while the scale drops, and staying hydrated. Both labels say the drug is meant to be used alongside diet and physical activity.

Our GLP-1 weight loss program is built around that. It pairs medication with a protein target, a resistance training prescription and peptide or hormone support where it fits. We measure skeletal muscle mass and body fat on an InBody 770 at every visit, so you can see whether you're losing fat or muscle, against your own baseline. Care starts with an 80+ biomarker panel, because thyroid function, blood sugar and nutrient gaps affect how you feel while you're eating less. If you're still choosing between medicines, Zepbound vs Mounjaro vs Wegovy vs Ozempic lays out how they differ.

Frequently Asked Questions

Is it better to inject Zepbound in the stomach or the thigh?

Neither is better for results. The prescribing information says tirzepatide reaches similar levels in the blood from the abdomen, thigh or upper arm. Choose the site that's most comfortable for you and rotate the exact spot each week.

Can I inject Zepbound in the same spot every week?

No. The instructions say to change the injection site with each weekly dose. You can stay in the same body area, such as your stomach, as long as you choose a different spot inside it. Reusing one spot raises the risk of pitted, thickened or lumpy skin.

Can I inject Zepbound into my own arm?

The label says another person should give the injection in the back of the upper arm. On your own, use your stomach or thigh.

What happens if I inject Zepbound into a muscle by mistake?

The label says to inject under the skin and not into a muscle or vein, but it doesn't describe what happens if you do. If you think an injection went in wrong, call your provider or Lilly at 1-800-545-5979 before your next dose rather than guessing.

Are Mounjaro injection sites the same as Zepbound's?

Yes. Both are tirzepatide, and both labels list the same three sites: the abdomen, the thigh, and the back of the upper arm given by another person, with the site rotated every week.

Do I need to let the pen warm up before injecting?

No. The single-dose pen instructions say it isn't necessary to warm the pen to room temperature.

Start Feeling Like Yourself Again

If you're starting a GLP-1 medication, or already on one and want more than a prescription and a pen, start with a plan that tracks muscle and fat from the first visit. It begins with a Free Discovery Call, then an 80+ Biomarker Test & Full Body Scan. Our Medical Team Reviews Everything, and a 60-Minute Provider Consultation builds a plan around your results.

Get Your Free Guide + $100 Voucher and start with a weight loss plan built around protecting muscle.

Med Matrix is a functional medicine clinic in South Portland, Maine, serving patients in Maine and New Hampshire.